TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27701901
Drug: No information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: No information about chemotherapy-related cognitive problems (control group)
Study: 23572323
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg after each haemodialysis session)
Study: 23572323
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg after each haemodialysis session)
Study: 16942566
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a weekly dose of 200,000 SQ-U
Study: 16942566
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a weekly dose of 24,000 SQ-U
Study: 12749277
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ranitidine and ecabet
Study: 10811145
Drug: Estriol (E3)
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (E3) treatment (2 mg/day) for 30 weeks
Study: 8626978
Drug: Total glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glycerin dose (volume x concentration)
Study: 1445476
Drug: Propionyl-L-carnitine 500
Normalized name: GLYCINE PROPIONYL-L-CARNITINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine 500 mg orally, 3 times a day for 180 days
Study: 31094126
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (dydrogesterone) 10 mg twice daily
Study: 31094126
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (cyclogest pessary) 400 mg daily per rectal use
Study: 25050521
Drug: Infliximab and
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab and etanercept combination therapy
Study: 20886606
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b (0.5 μg/kg/wk) and GM-CSF (125 mg/m² 3× weekly)
Study: 20886606
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg/d) alone
Study: 20886606
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b and GM-CSF
Study: 15150203
Drug: Pexelizumab (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553)
Study: 2685007
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human GH therapy (Norditropin; 2 IU/m2.day)
Study: 25092775
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) once every 2 weeks for nine cycles
Study: 25092775
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant chemotherapy (paclitaxel followed by ddAC)
Study: 23114287
Drug: Exogenous creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous creatine phosphate added to cardioplegic solution
Study: 11153670
Drug: Rifabutin 300-450
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300-450 mg daily
Study: 11153670
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rifabutin and clarithromycin
Study: 8365299
Drug: Maximal doses
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal doses of Ipratropium Bromide (80 micrograms)
Study: 28115474
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 300 units/mL (Gla‐300)
Study: 24993934
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily (arm A)
Study: 24993934
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg plus bicalutamide 50 mg daily (arm B)
Study: 24462367
Drug: Meals supplemented
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals supplemented with 1.4 g of cocoa extract (645.3 mg of polyphenols)
Study: 12759107
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg/day
Study: 12759107
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg/day
Study: 12759107
Drug: Granisetron 0
Normalized name: granisetron 0.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0 mg/day (control)
Study: 12759107
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups treated with a 21‐mg nicotine patch
Study: 10585155
Drug: Affinity oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affinity oxygenator with 10 ml of 25% albumin added to the pump prime (Albumin group)
Study: 8952015
Drug: Prophylactic antiepileptic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antiepileptic drugs (AEDs)
Study: 2009894
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg and Diltiazem 60 mg combination
Study: 2009894
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg alone
Study: 2009894
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg alone
Study: 6355056
Drug: Placebo (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (polyethylene glycol ointment and modified aqueous cream)
Study: 27828768
Drug: Natural Curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Curcumin (100 mg/L)
Study: 27828768
Drug: Photogem (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photogem (100 mg/L)
Study: 27828768
Drug: Natural Curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Curcumin (25 mg/L)
Study: 27828768
Drug: Photogem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photogem (25 mg/L)
Study: 23539534
Drug: PH-797804 3
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-797804 3 mg
Study: 23539534
Drug: PH-797804 6
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-797804 6 mg
Study: 23539534
Drug: PH-797804 3
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-797804 3 mg and 6 mg
Study: 19766947
Drug: PSUNC exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSUNC exposure (treatment)
Study: 12635671
Drug: dorzolamide 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: dorzolamide 3 times daily for 4 weeks
Study: 12635671
Drug: latanoprost once
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: latanoprost once daily for 4 weeks
Study: 9176828
Drug: Pediasure with
Normalized name: Pediasure with Fiber Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediasure with approximately 10 g total dietary fiber/l (PSF10)
Study: 1544291
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bromfenac
Study: 1544291
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bromfenac
Study: 1544291
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg bromfenac
Study: 1544291
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bromfenac
Study: 28440343
Drug: Sildenafil (high-dose)
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil (high-dose)
Study: 22801672
Drug: Escitalopram, 10
Normalized name: Escitalopram, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 10 mg/d (n = 90)
Study: 19862667
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride 3.75 g/day
Study: 7848349
Drug: Deponit 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deponit 5 (test patch)
Study: 25141907
Drug: α1‐adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1‐adrenoceptor antagonists (tamsulosin)
Study: 25141907
Drug: uroflowmetry biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: uroflowmetry biofeedback combined with α1‐adrenoceptor antagonists
Study: 16921684
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide insufflation at 6 L/min through a Jackson Pratt drain into the pericardium during cardiopulmonary bypass
Study: 12943177
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine acupuncture therapy and ROM exercise)
Study: 8829883
Drug: Lactobionate-based solutions
Normalized name: lactobionate
DrugBank: Lactobionic acid (DB16621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobionate-based solutions
Study: 8829883
Drug: Hypertonic citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic citrate solutions
Study: 8829883
Drug: Extracellular solutions
Normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracellular solutions
Study: 2072494
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 pethidine (group 1)
Study: 2072494
Drug: 0.7 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg.kg‐1 pethidine (group 2)
Study: 2072494
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (0.5 mg.kg‐1 and 0.7 mg.kg‐1 pethidine)
Study: 6418905
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose branched-chain amino acid (BcAA) hyperalimentation (45% BcAA)
Study: 6418905
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution (24.2% BcAA)
Study: 25041620
Drug: Intralesional recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional recombinant human epidermal growth factor (rhEGF) 75 μg, thrice-per-week for 8 weeks
Study: 20142693
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) thrice daily and physical therapy (PT) twice daily during hospitalization.
Study: 20142693
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) twice daily during hospitalization (Control group).
Study: 18613962
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapies (ACT)
Study: 15792396
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg once daily) alone
Study: 15792396
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg once daily) and telithromycin (800 mg once daily) given concomitantly
Study: 15792396
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg once daily) and clarithromycin (500 mg twice daily) given concomitantly
Study: 14622692
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs long-term
Study: 10499947
Drug: Prochlorperazine (PCZ)
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine (PCZ) 10 mg intravenous
Study: 10499947
Drug: Nonakathisic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonakathisic intravenous therapy (saline solution or antibiotics)
Study: 7049587
Drug: Amiloride/hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride/hydrochlorothiazide combination (2 tablets per day of 5 mg amiloride plus 50 mg hydrochlorothiazide)
Study: 7049587
Drug: Hydrochlorothiazide alone
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide alone (50 mg hydrochlorothiazide)
Study: 29464385
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg administered via i.v. 20 minutes before surgery completion)
Study: 29464385
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml administered via i.v. 20 minutes before surgery completion)
Study: 24673708
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL; 4 mg intravenously every 21-28 days)
Study: 24673708
Drug: Clodronate (CLO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (CLO; 1600 mg/d orally)
Study: 14657744
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with original operation and postoperative therapy, bone grafts from dissected spinous processes, grafts placed from three to five levels, orthosis applied for up to 1 month, neck collar recommended for 1 additional month.
Study: 10584416
Drug: Local addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local addition of ketoprofen (1:400) with 4 ml of 1% lidocaine
Study: 10584416
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without ketoprofen) with 4 ml of 1% lidocaine
Study: 8729628
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment (N = 49)
Study: 17044088
Drug: Neuromuscular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular therapy (NMT)
Study: 15199082
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg qd) for 4 days followed by aspirin (100 mg qd) for 7 days
Study: 15199082
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg qd) for 7 days after meloxicam
Study: 15199082
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg) for 2 days
Study: 9393424
Drug: Crestal incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal incision (1,705 implants)
Study: 9393424
Drug: Remote incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote incision (593 implants)
Study: 7943676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2-DG) 25.0 mg/kg
Study: 7943676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2-DG) 12.5 mg/kg
Study: 3370038
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after 24 hours of head-down bed rest
Study: 3370038
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after being seated for 1 hour
Study: 25590831
Drug: Synthetic mesh
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic mesh soaked in vancomycin solution (Group 2)
Study: 23147209
Drug: rimonabant 20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: rimonabant 20 mg/day
Study: 21519360
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (AP) 20 mg daily
Study: 21519360
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (AP) 40 mg daily
Study: 21519360
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (AP) 60 mg daily
Study: 21519360
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (AP) 30 mg twice daily
Study: 16480474
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g intravenously, 5 h apart (n = 40)
Study: 16480474
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg intramuscularly (n = 40)
Study: 10729298
Drug: Nasal application
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal application of oxygen at a constant flow of 2 l/min
Study: 10729298
Drug: Ambient air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient air at a constant flow of 2 l/min
Study: 8222122
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 20 mg/d)
Study: 3532605
Drug: New Rift
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Rift Valley fever vaccine (formalin‐inactivated, prepared in diploid fetal rhesus lung cells)
Study: 3532605
Drug: Various vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various vaccine lots
Study: 29426300
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 0.5 mcg daily for 6 weeks
Study: 28861980
Drug: Gushen Antai
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gushen Antai pills combined with progesterone
Study: 18677973
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate plus reproterol (DSCG/REP) inhalation 20 min before exercise challenge
Study: 18677973
Drug: Montelukast (MON)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (MON) oral treatment for 3 days
Study: 10561733
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of a serine protease inhibitor
Study: 10561733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no serine protease inhibitor)
Study: 8572007
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (ampicillin-sulbactam and amoxicillin-clavulanic acid)
Study: 31285376
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy under assumed ideal conditions
Study: 31285376
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy under current local resources (night time scenarios)
Study: 31285376
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy under current local resources (daytime scenarios)
Study: 31285376
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy under assumed ideal conditions (daytime scenarios)
Study: 25608583
Drug: darunavir 600
Normalized name: darunavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir 600 mg/100 mg
Study: 25608583
Drug: darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir 800 mg/100 mg
Study: 21708057
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg of DHEAS
Study: 16776915
Drug: Warfarin (adjusted-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose, INR 2.0 - 3.0)
Study: 16776915
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg - 160 mg once daily)
Study: 12584227
Drug: IFN-lamivudine combination
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IFN-lamivudine combination therapy
Study: 9880387
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge to community therapy
Study: 9880387
Drug: Therapy, meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy, meals on wheels, home help visits
Study: 2678880
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contraceptives
Study: 794978
Drug: Mazindol (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (tricyclic compound, non-amphetamine) for 8 weeks
Study: 23706546
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 100 mg bupivacaine in 100 mL normal saline solution
Study: 23706546
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 100 mg bupivacaine
Study: 3582722
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxycillin twice daily
Study: 3582722
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg amoxycillin three times daily